Nasdaq · CIK 0001720580
ACET Adicet Bio, Inc.
A
95 / 100
Material weaknesses
1
Restatements
0
Auditor changes
0
Late filings
0
Quarters with open weakness
1
Remediations
1
Deductions
20
Remediation credit
15
Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.
Disclosures, in the company's words
“During the fourth quarter of 2024, we identified a material weakness in our internal control over financial reporting which relates to cash disbursements. We concluded that this material weakness in our internal control over financial reporting occurred due to our internal controls having not been adequately designed to prevent or timely detect unauthorized cash disbursements.”
Remediation disclosed
- 10-Q · filed 2026-11-05 · source filing ↗
“We concluded that the remediation steps taken have been sufficient to remediate this material weakness as of the date of our Annual Report on Form 10-K for the year ended December 31, 2024.”
Filings read
- 10-Q · 2026-11-05read
- 10-Q · 2026-08-05queued
- 10-Q · 2026-05-13queued
- 10-K · 2026-03-12queued
- 10-Q · 2025-11-05queued
- 10-Q · 2025-08-07queued
- 10-Q · 2025-05-06queued
- 10-K · 2025-03-06queued
Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.